Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme ...
Researchers from Drexel University’s College of Arts and Sciences and College of Medicine have found a potential new therapeutic target for Alzheimer’s disease. Expanding on their previous research on ...
UniQure (NASDAQ:QURE) is one of the most promising low-cost stocks to buy now. On February 6, UniQure reported positive updated data from its Phase I/IIa trial of AMT-191, which is a gene therapy for ...
Morning Overview on MSN
Common enzyme tied to diabetes may unlock bold new Alzheimer’s treatment
A protein that has long frustrated diabetes researchers is suddenly at the center of a very different fight. By targeting an enzyme called protein tyrosine phosphatase 1B, or PTP1B, scientists are ...
Researchers present novel therapeutics that rejuvenate a previously undruggable mitochondrial regulator of aging through a new mode of enzyme activation. Leveraging a newly identified biophysical ...
AMT-191 has been granted both Orphan Drug and Fast Track designation by the U.S. Food and Drug Administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results